Palivizumab in the prophylaxis of respiratory syncytial virus infection

References

• Hall CB. Respiratory syncytial virus and parainfluenza virus. N. Engl. J. Med. 344(25), 1917–1928 (2001).
   PubMedGoogle Scholar
• Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am. J. Dis. Child. 140, 543–546 (1986).
   PubMedGoogle Scholar
• Kim HW, Arrobio JO, Brandt CD et al. Epidemiology of respiratory syncytial virus infection in Washington, DC. I. Importance of the virus in different respiratory tract disease syndromes and temporal distribution of infection. Am. J. Epidemiol. 98, 216–225 (1973).
   PubMed Web of Science ®Google Scholar
• Black CP. Systematic review of the biology and medical management of respiratory syncytial virus infection. Respir. Care 48, 209–231 (2003).
   PubMedGoogle Scholar
• Boyce TG, Mellen BG, Mitchel EF Jr, Wright PF, Griffin MR. Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J. Pediatr. 137, 865–870 (2000).
   PubMed Web of Science ®Google Scholar
• Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis-associated hospitalizations among US children, 1980–1996. J. Am. Med. Assoc. 282, 1440–1446 (1999).
   PubMed Web of Science ®Google Scholar
• Shay DK, Holman RC, Roosevelt GE, Clarke MJ, Anderson LJ. Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979–1997. J. Infect. Dis. 183, 16–22 (2001).
   PubMed Web of Science ®Google Scholar
• Pickering LK. Respiratory syncytial virus. In: Red Book: 2003 Report of the Committee on Infectious Diseases. American Academy of Pediatrics, IL, USA, 523–528 (2003).
   Google Scholar
• Abman SH, Ogle JW, Butler-Simon N, Rumack CM, Accurso FJ. Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis. J. Pediatr. 113, 826–830 (1988).
   PubMed Web of Science ®Google Scholar
• Kellner JD, Ohlsson A, Gadomski AM, Wang EE. Efficacy of bronchodilator therapy in bronchiolitis. A meta-analysis. Arch. Pediatr. Adolesc. Med. 150, 1166–1172 (1996).
   PubMed Web of Science ®Google Scholar
• Roosevelt G, Sheehan K, Grupp-Phelan J, Tanz RR, Listernick R. Dexamethasone in bronchiolitis: a randomised controlled trial. Lancet 348, 292–295 (1996).
   PubMed Web of Science ®Google Scholar
• Klassen TP, Sutcliffe T, Watters LK, Wells GA, Allen UD, Li MM. Dexamethasone in salbutamol-treated in-patients with acute bronchiolitis: a randomized, controlled trial. J. Pediatr. 130, 191–196 (1997).
   PubMed Web of Science ®Google Scholar
• Bulow SM, Nir M, Levin E et al. Prednisolone treatment of respiratory syncytial virus infection: a randomized controlled trial of 147 infants. Pediatrics 104, E77 (1999).
   PubMed Web of Science ®Google Scholar
• Richter H, Seddon P. Early nebulized budesonide in the treatment of bronchiolitis and the prevention of postbronchiolitic wheezing. J. Pediatr. 132, 849–853 (1998).
   PubMed Web of Science ®Google Scholar
• Fox GF, Everard ML, Marsh MJ, Milner AD. Randomised controlled trial of budesonide for the prevention of post-bronchiolitis wheezing. Arch. Dis. Child. 80, 343–347 (1999).
   PubMed Web of Science ®Google Scholar
• Cade A, Brownlee KG, Conway SP et al. Randomised placebo-controlled trial of nebulised corticosteroids in acute respiratory syncytial viral bronchiolitis. Arch. Dis. Child. 82, 126–130 (2000).
   PubMed Web of Science ®Google Scholar
• The PREVENT Study Group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 99, 93–99 (1997).
   PubMed Web of Science ®Google Scholar
• Respiratory syncytial virus immune globulin intravenous: indications for use. American Academy of Pediatrics Committee on Infectious Diseases, Committee on Fetus and Newborn. Pediatrics 99, 645–650 (1997).
   PubMedGoogle Scholar
• Press EM, Hogg NM. The amino acid sequences of the Fd fragments of two human gamma-1 heavy chains. Biochem. J. 117, 641–660 (1970).
   PubMed Web of Science ®Google Scholar
• Takahashi N, Noma T, Honjo T. Rearranged immunoglobulin heavy chain variable region (VH) pseudogene that deletes the second complementarity-determining region. Proc. Natl. Acad. Sci. USA 81, 5194–5198 (1984).
   PubMed Web of Science ®Google Scholar
• Johnson S, Oliver C, Prince GA et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J. Infect. Dis. 176, 1215–1224 (1997).
   PubMed Web of Science ®Google Scholar
• Piedimonte G, King KA, Holmgren NL, Bertrand PJ, Rodriguez MM, Hirsch RL. A humanized monoclonal antibody against respiratory syncytial virus (palivizumab) inhibits RSV-induced neurogenic-mediated inflammation in rat airways. Pediatr. Res. 47, 351–356 (2000).
   PubMed Web of Science ®Google Scholar
• Sabogal C, Auais A, Napchan G et al. Effect of respiratory syncytial virus on apnea in weanling rats. Pediatr. Res. 57, 819–825 (2005).
   PubMed Web of Science ®Google Scholar
• Palivizumab. A humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics 102, 531–537 (1998).
   PubMed Web of Science ®Google Scholar
• Feltes TF, Cabalka AK, Meissner HC et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J. Pediatr. 143(4), 532–540 (2003).
   PubMedGoogle Scholar
• Sorrentino M, Powers T. Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. The Palivizumab Outcomes Study Group. Pediatr. Infect. Dis. J. 19, 1068–1071 (2000).
   PubMed Web of Science ®Google Scholar
• Parnes C, Guillermin J, Habersang R et al. Palivizumab prophylaxis of respiratory syncytial virus disease in 2000–2001: results from The Palivizumab Outcomes Registry. Pediatr. Pulmonol. 35, 484–489 (2003).
   PubMed Web of Science ®Google Scholar
• Carbonell-Estrany X, Quero J. Hospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasons. Pediatr. Infect. Dis. J. 20, 874–879 (2001).
   PubMed Web of Science ®Google Scholar
• Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn. Pediatrics 102, 1211–1216 (1998).
   PubMed Web of Science ®Google Scholar
• Gelfand A, Cohen A, Boron M et al. RSV prophylaxis in 60 children with cystic fibrosis: results from the ‘Real World’ Experience – Palivizumab Outcomes Registry 2000–2003. Am. J. Respir. Crit. Care Med. 169, A386 (2004).
   Google Scholar
• Cohen AH, Boron ML, Dingivan C. A Phase IV study of the safety of Synagis (palivizumab) for prophylaxis of respiratory syncytial virus disease in children with cystic fibrosis. Proc. Am. Thor. Soc. 2, A189 (2005).
   Google Scholar
• Figueras-Aloy J, Carbonell-Estrany X, Quero J. Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33–35 weeks in Spain. Pediatr. Infect. Dis. J. 23, 815–820 (2004).
   PubMed Web of Science ®Google Scholar
• Law BJ, Langley JM, Allen U et al. The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr. Infect. Dis. J. 23, 806–814 (2004).
   PubMed Web of Science ®Google Scholar
• United States Food and Drug Administration, Synagis (Palivizumab), BLA Product Approval Information.
   Google Scholar
• United States Food and Drug Administration, FDA Safety Information and Adverse Event Reporting Program (1998).
   Google Scholar
• Mohan AK, Braun MM, Ellenberg S, Hedje J, Cote TR. Deaths among children less than two years of age receiving palivizumab: an analysis of comorbidities. Pediatr. Infect. Dis. J. 23, 342–345 (2004).
   PubMed Web of Science ®Google Scholar
• Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am. J. Respir. Cell. Mol. Biol. 161, 1501–1507 (2000).
   Google Scholar
• Stein RT, Sherrill D, Morgan WJ et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet 354, 541–545 (1999).
   PubMed Web of Science ®Google Scholar
• Piedimonte G, Hegele RG, Auais A. Persistent airway inflammation after resolution of respiratory syncytial virus infection in rats. Pediatr. Res. 55, 657–665 (2004).
   PubMed Web of Science ®Google Scholar
• Wenzel SE, Gibbs RL, Lehr MV, Simoes EA. Respiratory outcomes in high-risk children 7 to 10 years after prophylaxis with respiratory syncytial virus immune globulin. Am. J. Med. 112, 627–633 (2002).
   PubMed Web of Science ®Google Scholar
• Simoes EA, Carbonell-Estrany X, Kimpen J et al. Palavizumab use decreases risk of recurrent wheezing in preterm children. Eur. Respir. J. 24(Suppl. 48), 212 (2004).
   Google Scholar